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Abstract 
 
Objective 
Recently we have shown a significant reduction of cytokine-induced transcription of 
collagen type I and fibronectin in systemic sclerosis (SSc) skin fibroblasts upon 
treatment with Trichostatin A (TSA). Moreover, in a mouse model of fibrosis, TSA 
prevented the dermal accumulation of extracellular matrix. Here, we analyze 
silencing of HDAC7 as a possible mechanism of TSA to exert its anti-fibrotic function. 
 
 
Materials and methods  
Skin fibroblasts from patients with SSc were treated with TSA and/or TGF-β. 
Expression of HDACs (1-11), extracellular matrix proteins, connective tissue growth 
factor (CTGF) and intercellular adhesion molecule-1 (ICAM-1) were analyzed by 
Real-time PCR, Western blot and the Sircol Collagen assay. HDAC7 was silenced 
using siRNA.  
 
Results 
SSc fibroblasts did not show a specific pattern of expression of HDACs. TSA 
inhibited the expression of HDAC7 significantly whereas HDAC3 was up regulated. 
Silencing of HDAC7 decreased the constitutive and cytokine-induced production of 
collagen types I and III but not of fibronectin as TSA did. Most interestingly, TSA 
induced the expression of CTGF and ICAM-1, while silencing of HDAC7 had no 
effect on their expression.   
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Conclusions 
Silencing of HDAC7 appears to be not only as effective as TSA, but also a more 
specific target for the treatment of SSc, because it does not up regulate the 
expression of profibrotic molecules like ICAM-1 and CTGF. This observation may 
lead to the development of more specific and less toxic targeted therapies against 
SSc.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
SSc is an autoimmune disease characterized by widespread vascular changes and 
progressive fibrosis of skin and internal organs. The etiology and pathogenesis of 
SSc are still unknown. Currently no effective treatment is available to inhibit the 
progression of SSc.  
The term “epigenetics” refers to changes in gene activity, that are stable and 
inherited over rounds of cell division, but do not involve changes in the DNA 
sequence of the organism. Several epigenetic modifications have been described, 
such as DNA methylation and histone acetylation. In normal conditions, these 
modifications are balanced and reversible, but they may be altered in disease states. 
Epigenetic modifications have been shown to play a role in the pathogenesis of 
cancer as well as autoimmune and inflammatory disorders (1, 2). Recently, several 
publications reported epigenetic modifications in gene transcription in SSc (3-6). 
Therefore, the field of epigenetics may provide new therapeutic targets for treatment 
strategies.  
The DNA in eukaryotic cells is tightly wrapped around octamers of histone proteins, 
restricting its accessibility to factors involved in DNA replication and transcription. 
Posttranslational modifications of histone proteins induce changes in the structure of 
chromatin and therefore modify gene expression. Hyperacetylated histones are 
generally found in transcriptionally active and hypoacetylated histones in 
transcriptionally silent regions.  The acetylation state of chromatin proteins depends 
on the balance between the activities of HDACs and histone acetyltransferases 
(HATs). According to the structure and biologic activities, mammalian HDACs can be 
classified into four different classes: class I (HDAC1, 2, 3 and 8), class II (HDAC4, 5, 
6, 7, 9 and 10), class III (Sirt1-7) and class IV (HDAC11) (7). HDACs have been 
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shown to be promising therapeutic targets for cancer therapy, as well as for 
inflammatory or fibrotic diseases (5, 8, 9). 
Histone deacetylase inhibitors (HDACi) have emerged as a new class of agents for 
anticancer therapy. HDACi alter the balance of acetylation and affect many aspects 
of cellular function including cell growth, differentiation, cell death, cell-cell and cell-
matrix interactions, and inflammatory responses (10). One of the first discovered 
HDACi with anti-tumor activity was TSA. However, the toxicity of TSA is still being 
controversially discussed (11). Even though individual HDAC isoforms have 
distinctive physiological functions, most known hydroxamate HDACi target members 
of class I and class II rather non-selectively. The production of inhibitors for specific 
HDAC isoforms are now in the focus of the pharmaceutical industry (12). Therefore, 
there is increasing interest to unravel the property and function of each isoforms and 
to explore their individual roles in the pathogenesis of certain diseases.  
Recently, we have shown a significant reduction of cytokine-induced transcription of 
collagen type I and fibronectin in SSc skin fibroblasts upon treatment with TSA. In 
addition, we have demonstrated that the expression of total collagen protein in 
stimulated SSc skin fibroblasts was reduced by TSA. Moreover, TSA prevented the 
dermal accumulation of extracellular matrix in vivo in the mouse model of bleomycin-
induced fibrosis (6). In the present study we analyzed the molecular mechanisms of 
TSA-mediated reduction of extracellular matrix in SSc. In order to define new target 
molecules, we measured the transcriptional level of individual HDACs (1-11) in SSc 
fibroblasts treated with TSA. We could show that TSA, as a non-specific HDACi, has 
different effects on individual HDACs. Most interestingly, TSA almost completely 
inhibited the transcription of HDAC7, whereas the transcripts for HDAC3 were up 
regulated. Specific gene knockdown of HDAC7 in SSc fibroblasts resulted in a 
reduced production of collagen types I and III both on the mRNA and protein level. 
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Therefore, therapies that specifically target HDAC7 could be safer than the non-
selective HDACi TSA in the treatment of SSc, because silencing of HDAC7 does not 
increase the expression of pro-fibrotic molecules ICAM-1 and CTGF. Our results 
strongly support targeting HDAC7 to generate a more specific and less toxic anti-
fibrotic agent for the treatment of SSc.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and Methods 
 
Patients and fibroblast cultures 
Normal and SSc fibroblasts were obtained from the skin of patients with scleroderma 
and healthy controls. All patients fulfilled the criteria for SSc as suggested by LeRoy 
et al (13). All patients signed a consent form approved by the institutional review 
board of the Kaunas University, Lithuania. Primary cultures of human dermal 
fibroblasts were established by outgrowth and were cultured in Dulbecco`s modified 
Eagle`s medium (DMEM) containing 10% heat inactivated fetal calf serum (FCS), 25 
mM HEPES, 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine and 2.5 
μg/ml amphotericin B (all Gibco BRL, Basel, Switzerland). Fibroblasts of passages 3-
8 in monolayer culture were used for experiments. Cells were treated with 10nM-2μM 
of TSA (Sigma, Buchs SG, Switzerland).  
 
TaqMan RT-PCR 
Total RNA was isolated from cultured cells using RNeasy-kit including DNAse 
treatment (Qiagen, Hombrechtikon, Switzerland) according to the instructions of the 
manufacturer. To generate cDNA, total RNA (300-500ng) was reverse transcribed 
using murine leukemia virus (MuLV) reverse transcriptase (RT) (2.5 U/μl), random 
hexamers (2.5 μM), dNTPs (2 mM each) and RNase inhibitor (1U/μl) (all Applied 
Biosystems, Rotkreuz, Switzerland). The reverse transcriptase reaction was 
performed in a total volume of 20 μl in a GeneAmp PCR cycler (Applied Biosystems, 
Rotkreuz, Switzerland) at 25°C for 10 min, followed by 30 min at 48°C and by 5 min 
at 95°C. Samples without enzyme in the reverse transcription reaction were used as 
negative controls (NRT) to exclude contamination with genomic DNA. Quantification 
of specific mRNA was performed by single reporter and Sybr Green Real-time PCR 
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using the ABI Prism 7700 Sequence Detection System (Applied Biosystems) as 
described (14). Pre-developed primer-probes were used for HDAC1, 2, 8, PDGF-B 
(platelet-derived growth factor) and PDGFR-β (platelet-derived growth factor 
receptor) (Applied Biosystems). Sybr Green Real-time PCR was performed for 
human COL1A1, fibronectin (6), ICAM-1: fwd 5`-CCT ATG GCA ACG ACT CCT TC -
3`, rev TGC GGT CAC ACT GAC TGA G -3; COL3A1: fwd 5`-GGC ATG CCA CAG 
GGA TTC T-3`, rev 5`-GCA GCC CCA TAA TTT GGT TTT-3`;  HDAC3: fwd 5`-ATG 
CAA GGC TTC ACC AAG AG-3`, rev 5`-CAG TCA TCG CCT ACG TTG AA-3`; 
HDAC4: fwd 5`-TGT ACG ACG CCA AAG ATG AC-3`, rev 5`-CGG TTC AGA AGC 
TGT TTT CC-3`; HDAC5: 5`-CAG CAG GCG TTC TAC AAT GA-3`, rev 5`-CGATGC 
AGAGAG ATG TAG AGC A-3`; HDAC6: fwd 5`-GAA AGT CAC CTC GGC ATC AT-
3`, rev 5`-TAG TCT GGC CTG GAG TGG AC-3`; HDAC7: fwd 5`-ATG GGG GAT 
CCT GAG TAC CT-3`, rev 5`-GAT GGG CAT CAC GAC TAT CC-3`; HDAC9: fwd 5`-
CTG GAG CCC ATC TCA CCT T-3`, rev 5`-TCA TCA TCC TGA GGT CTG TCC-3`; 
HDAC10: fwd 5`-GCC GGA TAT CAC ATT GGT TC-3`, rev 5`-GAC GCT TCC TGT 
TGG ATG A-3`; HDAC11: fwd 5`-GGT CAG GAA GGG GTA CAG GT-3`, rev 5`-ATT 
GAG GGG GAA CTC CAG AT-3`. To confirm specific amplification by Sybr Green 
PCR, dissociation curve analysis was performed for each primer pair, and NRT 
controls and water controls were analyzed for all samples. Amounts of loaded cDNA 
were normalized using a predeveloped 18S assay (PE Applied Biosystems) as an 
endogenous control. Differential gene expression was calculated with the threshold 
cycle (Ct) and the comparative Ct method for relative quantification. Only samples 
with a difference of at least 4 cycles between the signals in cDNA samples and NRT 
(corresponding to a 16-fold difference in the expression) were considered for the 
calculations. All experiments were performed in duplicates. 
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 Collagen measurements 
Total soluble collagen in cell culture supernatants was quantified using the SirCol 
collagen assay (Biocolor, Belfast, Northern Ireland). For these experiments, confluent 
cells were incubated for 24h with 40 μl DMEM/ 10% FCS per cm2 of culture dish 
surface. 1 ml of the Sirius Red dye, an anionic dye that reacts specifically with [Gly-X-
Y]n tripeptide in the triple helix sequence of mammalian collagens under assay 
conditions, was added to 100μl supernatant and incubated under gently rotation for 
30 min at room temperature. After centrifugation for 10 min at 12000 g, the collagen-
bound dye was re-dissolved with 1 ml of 0.5 M NaOH and the absorbance was 
measured at 540 nm in a MRX ELISA reader (Dynex technologies). All samples were 
measured in duplicates. 
 
Western blot analysis 
For Western blot analysis, SSc skin fibroblasts (2x105 cells per well) were incubated 
in the absence or presence of TSA for 48h. Whole cell lysates were prepared by 
lysing cells in 2x concentrated Lemmli buffer (100 mM Tris HCl [pH 6.8], 40% 
glycerol, 10% sodium dodecyl sulfate [SDS], 0.7M β-mercaptoethanol, and 0.0005% 
bromphenol blue). Proteins were separated on a SDS–polyacrylamide gel and 
transferred to nitrocellulose membranes. Membranes were blocked for 1h at room 
temperature in 5% non-fat dry milk with 0.05% Tween 20 in TBS (pH 7.4) and were 
probed overnight at 4°C with antibodies against HDAC7, collagen type I, collagen 
type III, ICAM-1, PDGF-B, PDGFR-β and CTGF (Santa Cruz, CA, USA) or α-tubulin 
(Sigma). The blots were washed and incubated for 1h at room temperature with 
HRP-conjugated secondary antibodies (Jackson Immunoresearch, Magden, 
switzerland) in 5% non-fat dry milk with 0.05% Tween 20 in TBS (pH 7.4). Bound 
 9
 10
antibodies were visualized using enhanced chemiluminescence (Amersham 
Pharmacia Biotech, Little Chalfont, UK). Evaluation of the expression of specific 
proteins was performed by the Alpha imager Software system (Alpha Innotech, San 
Leandro, CA) via pixel quantification of the electronic image. 
 
Small interfering RNA (siRNA) 
Fibroblasts from patients with SSc were transfected using Amaxa Basic Nucleofector 
Kit (Amaxa biosystems) as described (14). For silencing of HDAC7, we used HDAC7 
siRNA (Santa Cruz / Qiagen) and scrambled siRNA representing an irrelevant coding 
siRNA (Applied Biosystems) as control siRNA which does not target any gene 
product. The protocol used has been optimized and recommended by the 
manufacturer. Briefly, proper amounts of cells (5 x 105 cells) were resuspended in 
100μl of nucleofector solution, mixed with 5l of siRNA (from a 10uM solution) and 
transfection was done using a nucleofector device (Program U23). After 24h 
incubation, fresh medium was added and the cells were incubated for another 24h 
before RNA extraction.   
 
Statistics 
All data are expressed as mean ± standard deviation. Statistical analysis was 
performed using the Mann–Whitney test (SPSS software). P-values <0.05 were 
considered significant.  
 
Results  
No disease specific pattern of mRNA expression of HDACs in SSc skin 
fibroblasts  
SSc fibroblasts (n=5) and skin fibroblasts from healthy controls (n=4) were analyzed 
for the expression of all known HDACs (1-11) by TaqMan Real-time PCR. Comparing 
the delta Ct levels, there was no significant difference in the constitutive expression 
pattern of HDACs in fibroblasts from patients with SSc and healthy controls (Figure 
1A). As we focus on HDAC7 in the present study, the expression of this particular 
HDAC was measured also on protein level. The expression of HDAC7 in SSc 
fibroblasts was not different from healthy controls (Figure 1B). In conclusion, 
fibroblasts from patients with SSc show no disease specific pattern of HDACs on the 
transcriptional level. 
 
Different effects of TSA on the expression of HDAC3 and HDAC7 in SSc 
fibroblasts 
TSA is considered to be a non-specific HDAC inhibitor. Nevertheless, the direct 
effects of TSA on the expression of individual HDACs (1-11) in SSc fibroblasts have 
not been investigated so far. Therefore, we treated SSc fibroblasts with TSA (2M) 
(6) for 24h and analyzed the mRNA expression of HDAC 1-11 by TaqMan Real-time 
PCR. HDAC7 mRNA was strongly reduced to 0.06 ± 0.01 fold (p ≤ 0.001) after 
treatment with TSA. HDAC3 mRNA was increased by TSA to 5.13 ± 1.46 fold (p ≤ 
0.002) (Figure 1C). The transcription levels of all other HDACs were down regulated 
by TSA (HDAC1: 0.75 ± 0.46, HDAC2: 0.59 ± 0.19, HDAC4: 0.75 ± 0.14, HDAC5: 
0.85 ± 0.23, HDAC6: 0.53 ± 0.15, HDAC8: 0.87 ± 0.06, HDAC9: 0.35 ± 0.06, 
HDAC10: 0.67 ± 0.20, HDAC11: 0.67 ± 0.10, n=3 for all). The results on mRNA level 
for HDAC3 and HDAC7 could be confirmed on the protein level by Western blot 
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(Figure 1D). Densitometric analysis of the Western blots showed that TSA reduced 
the expression of HDAC7 to 0.037 ± 0.05 fold (n=3, p<0.05) and increased the 
expression of HDAC3 to 2.19 ± 0.76 fold (n=3, p<0.05). In conclusion, we found the 
most pronounced effects of TSA on the expression of two individual HDACs, namely 
HDAC3 and HDAC7.  
 
Expression of different types of collagen after TSA treatment 
Patients with SSc have increased levels of collagen types I and III, with type I being 
the most abundant (15). In order to examine whether TSA regulates the expression 
of collagen, we performed a TaqMan Real-time PCR analysis for COL1A1 and 
COL3A1 in SSc fibroblasts (n=5). TSA down regulated the mRNA expression of 
COL1A1 and COL3A1 by 48 ± 6 and 67 ± 9% respectively (Figure 2A). Western blot 
was done to confirm the results on the protein level (Figure 2B). Densitometric 
analysis of the Western blots revealed a reduction of collagen types I and III by TSA 
to 0.23 ± 0.09 and 0.13 ± 0.02 fold respectively (n=3, p<0.05). To the same extent, 
expression of collagen types I and III was reduced by TSA after TGF-β stimulation 
(data not shown). Therefore, constitutive and induced expression of different types of 
collagen was down regulated after treatment with TSA.  
 
Specific gene knockdown of HDAC7 
As shown above, HDAC7 was considerably down regulated after treatment with TSA. 
To test whether the effects of TSA on SSc fibroblasts were mainly mediated through 
the down regulation of HDAC7, HDAC7 was knocked down using RNAi approach. As 
demonstrated in Figure 3A, gene expression of HDAC7 was suppressed by 76.20 ± 
8.48% (n=10, p=0.001) in HDAC7 siRNA treated cells after 48h of transfection 
compared to RNAi control. HDAC7 was also down regulated on protein level after 
 12
72h of transfection (Figure 3B), demonstrating the successful knockdown of HDAC7 
by siRNA. 
  
Effect of specific gene knockdown of HDAC7 on the expression of HDAC3 
Since we observed a significant down regulation of HDAC7 after TSA treatment, 
while the expression of HDAC3 was up regulated, we wanted to evaluate whether the 
expression of HDAC3 was affected by HDAC7 silencing. Therefore, we measured the 
expression level of HDAC3 after knockdown of HDAC7 in SSc fibroblasts (n=6). 
Using TaqMan Real-time PCR and Western blot, we observed no changes in the 
levels of HDAC3 expression, neither on the mRNA nor on the protein level (Figures 
3C and D).        
 
Expression of extracellular matrix proteins after HDAC7 silencing  
To address the question whether the effects of TSA on extracellular matrix (ECM) 
components are mediated through HDAC7, we investigated the expression of ECM 
proteins after HDAC7 specific gene knockdown. Whereas the expression of 
fibronectin remained unchanged (data not shown), both constitutive and cytokine-
induced gene expression of COL1A1 and COL3A1 were significantly reduced by 
silencing of HDAC7. The constitutive and TGF-β induced down regulation of mRNA 
levels for COL1A1 were 27.0 ± 2.4% (n=6, p<0.05) and 36.0 ± 14% (n=7, p<0.05) 
and for COL3A1 were 23.0 ± 4.0% (n=5, p<0.05) and 43.0 ± 9.0% (n=5, p<0.05) 
respectively (Figure 4A). Western blot analysis was done to confirm the results on 
protein level (Figures 4B and C). Additionally, using the Sircol Collagen assay, the 
production of total soluble collagen was found to be reduced by 26 ± 5.7%, as shown 
in Figure 4D (n=5, p<0.05). In conclusion, we found a significant down regulation in 
the expression of collagen types I and III after specific gene knockdown of HDAC7. 
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 Effects of HDAC7 silencing on the expression of PDGF-B and PDGFR-β in SSc 
fibroblasts 
PDGF plays an important role in the pathogenesis of SSc. Even though it is almost 
undetectable in healthy skin, studies have revealed the increased presence of PDGF 
and PDGF receptors in SSc skin biopsies (16). According to Mottet et al, HDAC7 
silencing in endothelial cells up regulated the expression of PDGF-B and its receptor 
(PDGFR-β) (17). In order to examine whether gene knockdown of HDAC7 alters the 
expression of PDGF-B and PDGFR-β in SSc fibroblasts, we analyzed changes in the 
transcript expression levels of these genes in cells treated with HDAC7 siRNA (n=6 
each). As it’s shown in Figures 5A and B, there was no significant change in the 
levels of PDGF-B and PDGFR-β comparing HDAC7 siRNA with RNAi control cells. 
Western blot was done to confirm the results on protein level (Figures 5C and D). In 
conclusion, silencing of HDAC7 had no significant effect on the expression of PDGF-
B and PDGFR-β in SSc fibroblasts.    
 
TSA up regulates the expression of CTGF and ICAM-1 while the expression of 
these molecules remains unchanged in SSc fibroblasts silenced for HDAC7   
CTGF is induced by TGF-β and modulates fibroblast cell growth but it also mediates 
many of the pro-fibrotic actions of TGF-β (18). ICAM-1, an inducible surface 
glycoprotein that promotes adhesion in immunological and inflammatory reactions, 
plays a role in a variety of inflammatory and neoplastic diseases. ICAM-1 also 
contributes significantly to the development of skin fibrosis, especially via ICAM-1 
expression in skin fibroblasts (19). To investigate whether acetylation induced by 
TSA and specific gene knockdown of HDAC7 might play a role in the regulation of 
CTGF and ICAM-1 proteins, we analyzed the expression of CTGF and ICAM-1 after 
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TSA treatment as well as after silencing of HDAC7 by Western blot. As shown in 
Figure 6A, CTGF and ICAM-1 were up regulated after 48h treatment with TSA to 
2.55 ± 0.19 fold (n=3, p<0.05) and to 21.34 ± 16.71 fold (n=3, p≤0.05) respectively. 
Of interest, the expression of CTGF and ICAM-1 in HDAC7 siRNA treated cells 
remained unchanged compared to cells treated with siRNA control (Figure 6B). It can 
be concluded that silencing of HDAC7 in contrast to TSA does not induce the 
expression of the pro-fibrotic molecules CTGF and ICAM-1 in SSc fibroblasts and 
therefore might be a more specific anti-fibrotic therapeutic target than TSA.  
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
The results of our present study demonstrate that silencing of HDAC7, a member of 
class II HDACs, might be a more specific and effective anti-fibrotic therapeutic 
approach in SSc than the use of TSA. Silencing of HDAC7 significantly reduced the 
excessive production of extracellular matrix proteins, a characteristic feature of SSc 
fibroblasts, without increasing other known pro-fibrotic molecules such as ICAM-1 
and CTGF.  
Recently, we have shown that the non-selective HDAC inhibitor TSA blocks the 
cytokine-induced production of collagen type I and fibronectin in fibroblasts from 
patients with SSc. In addition, in the bleomycin-induced mouse model of skin fibrosis, 
TSA prevented the dermal accumulation of extracellular matrix in vivo (6). In the 
present study we show for the first time that TSA did not only block the enzymatic 
activity of HDAC, but additionally regulates the protein level of selective targets by 
influencing their transcription. Subsequently, almost all transcripts of HDACs were 
reduced by TSA. However, the most interesting finding was that although TSA almost 
completely inhibited the transcription of HDAC7, a member of class II HDACs; 
HDAC3, a member of class I HDAC was significantly up regulated after treatment by 
TSA. This dual function of regulating protein activity and protein expression by TSA in 
fibroblasts from patients with SSc has not been described yet.  
Based on this observation we concluded that the down regulation of HDAC7 
represents the anti-fibrotic mechanism of TSA and suggest here that silencing of 
HDAC7 may be a more specific and safer treatment for SSc than TSA.   
TSA is one of the first discovered natural HDAC-inhibitors targeting the zinc-
containing HDAC classes I, II and IV, but not the NAD+-dependent class III enzymes 
(11). Despite the ubiquitous distribution of HDACs in the cells, HDACi such as TSA 
selectively alter only a relative small proportion of the expressed genes (2-10%) (20). 
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Moreover, in one study with human lymphoid cell lines TSA altered 2% of the 
expressed genes only (8 genes out of approximately 340 examined) (21). It is 
remarkable that in all these studies, roughly similar numbers of genes were down 
regulated and up regulated. For example in a study with a T cell leukaemia cell line 
22% of expressed genes were altered by HDACi with approximately similar numbers 
being up regulated and repressed (22). 
TSA is still considered as the reference compound of hydroxamic-acid containing 
HDACi although the costly and highly inefficient production encouraged the search 
for alternative drugs (23). TSA is one of the most potent HDACi that exerts its effects 
at very low concentrations (nanomolar) but it is still controversially discussed 
because of its poor bioavailability in vivo due to an extensive biotransformation or 
instability (20, 24-26). Unfortunately, none of the numerous HDACi is specific for 
single isoforms of HDAC, but few drugs show preferences for groups or single 
HDACs. FK228, for example shows some preference for class I HDACs, and tubacin 
specifically targets HDAC 6 (27, 28). Therefore, there is a challenging task to develop 
a new generation of HDACi with improved specificity for certain HDAC isoforms and 
an increased efficacy compared to the pan-inhibitors such as TSA and 
suberoylanilide hydroxamic acid (SAHA) (29).  
Recently, we gave evidence that TSA in vitro predominantly abrogates the cytokine-
induced production of excessive extracellular matrix, and that it prevents fibrosis in a 
mouse model of bleomycin-induced fibrosis. Therefore, we favored the hypothesis 
that TSA might serve as early strategy for the treatment of fibrosis. However, in the 
present study, we demonstrate that TSA also up regulates the expression of CTGF 
and ICAM-1, both characteristic players in the pathogenesis of SSc. The production 
of extra-cellular matrix proteins is induced in fibroblasts by TGF-beta in the early 
stage and is subsequently maintained by CTGF (30, 31). Additionally, it has been 
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shown that the expression of CTGF correlates with the severity of fibrosis (32). 
Matsushita et al demonstrated that ICAM-1 deficiency attenuates the development of 
skin fibrosis in the tight-skin mouse model (19). Therefore, the up regulation of CTGF 
and ICAM-1 might counteract the value of TSA as an anti-fibrotic drug.  
Of interest, in the present study we could demonstrate that TSA significantly blocked 
the transcription of HDAC7. Our results are supported by the recent publication from 
Dokmanovic et al who reported that the hydroxamatic acid-based HDACi Vorinostat 
(SAHA), which is similar to TSA, selectively down regulated HDAC7 in several cancer 
cell lines and to a lesser extent also in normal foreskin fibroblasts with little or no 
effect on the expression of other class II HDACs. Vorinostat has been approved for 
clinical treatment, and the authors suggest that the reduced expression of HDAC7 
might serve as a biomarker for a response to treatment (33).  
HDAC7 belongs to the class II HDACs that show a tissue or cell-specific expression 
and shuttle between the nucleus and the cytoplasm upon certain cellular signals. 
Nucleocytoplasmatic shuttling has been observed for all class II HDACs and reflects 
a putatively important regulatory mechanism. However, it needs to be stressed that 
HDAC7 is expressed in heart and lung tissues, placenta, pancreas, and skeletal 
muscle as well as in CD4/CD8 double positive thymocytes (34-37). Null mouse 
embryos for HDAC7 display defects in the development of blood vessels and their 
integrity (38). Moreover, HDAC7 protein has been implicated into several biological 
processes, including regulation of gene expression either as co-activator or co-
repressor (39, 40), and plays a role in T cell differentiation by inducing Nur77 (35). 
The enzymatic activity of HDAC7 maps to the carboxyl-terminal domain and seems 
to be dependent on the interaction with the class I HDAC, HDAC3. The binding of 
these two HDACs might be mediated by the transcriptional co-repressors SMRT and 
N-CoR that simultaneously bind class II HDACs and HDAC3 (41). Accordingly, it has 
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been recently reported that silencing of HDAC7 has also profound effects on 
endothelial cells. Mottet et al gave evidence of an altered migration of endothelial 
cells (HUVECs) upon silencing of HDAC7 (17). They could show that this disturbance 
was at least in part due to an up regulation of PDGF-B and PDGFR-β. However, in 
our study, silencing of HDAC7 in SSc dermal fibroblasts did not affect the expression 
of PDGF-B and PDGFR-β.  
The impact of HDAC7 on the vascularisation was underlined by another study 
performed by Chang et al. This study showed that HDAC7 plays a key role in the 
maintenance of vascular integrity by repressing matrix metalloproteinase 10 in 
HUVEC cells (38). Whether the influence of silencing of HDAC7 on angiogenesis, 
shown in HUVEC cells, also occurs in the skin of patients with SSc, is not yet clear.  
 In our study we could show that TSA inhibited the expression of HDAC7 and up 
regulated the expression of HDAC3 in fibroblasts from patients with SSc. However, 
silencing of HDAC7 by siRNA did not affect the level of expression of HDAC3 neither 
on the mRNA nor on the protein level. Therefore, we conclude that the anti-fibrotic 
effects of TSA are mediated by HDAC7 independently of HDAC3. In the present 
study we demonstrated that specific gene knockdown of HDAC7 similarly to TSA 
reduces significantly both, the cytokine (TGF-)-induced as well as the constitutive 
production of the extracellular matrix proteins collagen types I and III. As compared to 
TSA, silencing of HDAC7 does not affect the expression of fibronectin. However, the 
most pronounced advantage of silencing HDAC7 is the specific anti-fibrotic effect. In 
contrast to TSA, silencing of HDAC7 did not influence the expression levels of the 
pro-fibrotic molecules CTGF and ICAM-1 in SSc fibroblasts. Therefore, silencing of 
HDAC7 might be a new and promising approach for the anti-fibrotic treatment of SSc. 
 
 
Figure Legends 
  
Figure 1: Expression of HDACs in SSc vs. normal skin fibroblasts and effects 
of TSA on the expression levels of HDAC3 and HDAC7 in SSc fibroblasts 
(A) mRNA expression levels of HDAC1 to -11 were analyzed by Real-time PCR in 
SSc fibroblasts (n=5) and fibroblasts from healthy controls (n=4). Results are 
expressed as mean ± SD of x-fold change. Levels of expression in healthy fibroblasts 
are considered as 1. (B) Total cellular extracts from normal and SSc fibroblasts were 
analyzed by Western blot with anti-HDAC7 antibodies. The same samples were 
analyzed with antibodies against α-tubulin for normalization. (C) mRNA levels of 
HDAC3 (n=6) and HDAC7 (n=7) in untreated and TSA treated (2μM for 24h) SSc 
fibroblasts, analyzed by TaqMan Real-time PCR. Values are mean ± SD. Levels of 
expression in untreated cells (control) is considered as 1 (white bars), and the effect 
of TSA (black bars) is shown as x-fold change relative to control. (D) Protein levels of 
HDAC3 and HDAC7 after TSA treatment, determined by Western blot analysis. 
Untreated cells were used as controls, and the expression level of -tubulin was 
used for normalization. Results shown are from 3 independent experiments.  
 
Figure 2: Effects of TSA on the expression of different types of collagen 
 (A) Real-time PCR quantification of COL1A1 and COL3A1 after treatment with TSA, 
as compared to control (untreated cells). The expression level of 18S was used for 
normalization and results show the mean ± SD of 5 individual samples. (B) Western 
blot was used to assess the expression of collagen types I and III on the protein level 
after incubation with TSA for 48h. The same cell extracts were analyzed with 
antibodies against α-tubulin for normalization.  
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Figure 3: Transfection efficacy of HDAC7 siRNA and expression of HDAC3 after 
specific gene knockdown of HDAC7 
(A) Levels of mRNA for HDAC7 after specific gene knockdown using the siRNA, 
assessed by TaqMan Real-time PCR. Results are the mean ± SD from 10 different 
experiments. (B) Western blot shows the expression of HDAC7 protein after inhibition 
with siRNA. The same extracts were incubated with antibodies against α-tubulin as 
control. (C) Expression of HDAC3 in cells treated with HDAC7 siRNA was analyzed 
by TaqMan Real-time PCR. Results are the mean ± SD fold change in levels of 
mRNA relative to the control group (considered as 1). Data are representative of 6 
individual samples from different patients. (D) Effect of HDAC7 gene knockdown on 
the levels of HDAC3 protein in SSc fibroblasts (n=3), measured by Western blot. To 
control for variability of loading and transfer, membranes were reprobed with human 
anti-α-tubulin.             
 
Figure 4: Expression of different types of collagen in HDAC7 siRNA treated SSc 
fibroblasts 
(A) Constitutive and TGF-β induced levels of mRNA for COL1A1 and COL3A1 in 
HDAC7 siRNA fibroblasts (black bars) compared to RNAi control (white bars), 
estimated by quantitative TaqMan Real-time PCR. Values are the mean ± SD change 
in percent from 6 individual samples. (B) Total cellular extracts from HDAC7 siRNA 
and RNAi control fibroblasts were analyzed by Western blot with anti-collagen type I 
and anti-collagen type III antibodies. The same extracts were analyzed with 
antibodies against α-tubulin as control. (C) Western blot analysis for collagen types I 
and III in whole cell lysates of TGF-β stimulated SSc fibroblasts transfected with 
HDAC7 siRNA and RNAi control. Expression of α-tubulin was used for normalization. 
(D) Total soluble collagen production in supernatants of HDAC7/siRNA fibroblasts as 
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compared to siRNA control, measured by the Sircol collagen assay. The amount of 
collagen in cells transfected with RNAi control considered as 100% (white bar) and 
the regulation by gene knockdown of HDAC7 (black bar) is shown relative to the 
control. The data represent the mean ± SD from 5 independent experiments.  
 
Figure 5: Expression of PDGF-B and PDGFR-β in HDAC7 siRNA treated 
fibroblasts 
(A, B) mRNA expression of PDGF-B and PDGFR-β in cells transfected with HDAC7 
siRNA (black bar) compared to RNAi control (white bar) was analyzed by Real-time 
PCR. Results are shown as the mean ± SD (n=6 each). (C, D) Western blots 
showing PDGF-B (n=2) and PDGFR-β (n=3) in whole cell lysates of SSc fibroblasts 
transfected with HDAC7 siRNA and RNAi control. The same extracts were analyzed 
with antibodies against α-tubulin as control.  
 
Figure 6: Expression of CTGF and ICAM-1 in TSA treated cells and HDAC7 
siRNA treated fibroblasts  
(A) Western blot analysis of CTGF and ICAM-1 in cells obtained from patients with 
SSc (n=2) treated with TSA after 48h. Levels of α-tubulin served as a loading control. 
(B) SSc fibroblasts (n=2) silenced for HDAC7 (HDAC7 siRNA) and controls (control 
siRNA) were analyzed for the expression of CTGF and ICAM-1 by Western blot. 
Expression of α-tubulin was used for normalization.  
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